VIVO - Meridian Bioscience, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Meridian Bioscience, Inc.

3471 River Hills Drive
Cincinnati, OH 45244
United States
513-271-3700
http://www.meridianbioscience.com

SectorHealthcare
IndustryDiagnostic Substances
Full Time Employees640

Key Executives

NameTitlePayExercisedAge
Mr. John A. KraeutlerExec. Chairman819.88k93.53k70
Mr. Richard L. EberlyExec. VP, Pres & Chief Commercial Officer406.56kN/A57
Ms. Melissa A. LuekeCFO, Principal Financial & Accounting Officer, Exec. VP and Sec.360.54k94.08k55
Mr. Lawrence J. BaldiniExec. VP & Pres of Global Operations379.2kN/A59
Dr. Vecheslav A. ElaginExec. VP of R&D and Chief Scientific OfficerN/AN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.

Corporate Governance

Meridian Bioscience, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.